BUZZ-Aeterna Zentaris Inc: Licenses lead drug
** Drug developer's U.S.-listed shares up 15 pct at $3.75
** Company says signed license agreement with Orient EuroPharma's unit for commercializing its lead experimental anti-cancer drug, Zoptrex, in Taiwan and nine countries in Southeast Asia
** Company will also license intellectual property related to Zoptrex
** Orient has also agreed to make additional payments and royalties to the company upon achieving regulatory and commercial milestone
** Up to Friday's close, stock had fallen 27 pct this year
© Thomson Reuters 2017 All rights reserved.